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Annotation. The study of endotelio- and cardioprotective activity of finished dosage forms – 
tablets, film-coated, containing 10 mg of phenolic nature KUD-975, was shown a statistically 
significant decrease in blood pressure and the coefficient  of endothelial dysfunction on the 
background of simulation L-NAME-induced pathology. In the group of animals treated with 
KUD975 found a statistically significant increase in the concentrations of stable metabolites of 
nitric oxide, which in addition to the normalization of vasodilation says about 
endothelioprotektive action of the compounds studied. The initial values of the functioning of the 
left ventricle of the heart during treatment with KUD975 found hypodynamic action, which 
resulted in a decrease in the absolute values of the heart left ventricle pressure, + dp / dt, -dp / dt. 
Results of the study of the functional state of the myocardium during exercise testing, and 
histological evaluation of the myocardium revealed distinct cardioprotective effects in the study 
of KUD975 at a dose of 3 mg / kg, expressed in preventing the increase adrenoreactivity, 
exhaustion myocardial reserve during the sample to the load resistance and hypodynamic 
restructuring physiological response to the report on hypoxia / reoxygenation compared with 
animals that have modeled the endothelial dysfunction. 
Keywords: endothelial dysfunction, arginase inhibitors, the compounds of phenolic nature. 
 
Introduction.  
The endothelial cells line the luminal surface of 
all blood vessels and are involved in numerous 
regulatory functions, such as the control of 
contraction and proliferation of vascular smooth 
muscle, adhesion of leucocytes and platelets, 
permeability and inflammatory responses. The 
endothelium also possesses thrombolytic and 
fibrinolytic properties. In addition, its metabolic 
activity regulates the oxidation of plasma lipids, the 
formation of angiotensin I1 and the degradation of 
circulating catecholamines and kinins [1]. 
Although nitric oxide appears to be the major 
vasodilator released by endothelial cells in a vast 
majority of blood vessels, other substances, some of 
them still unknown, may play a role as well. 
Furthermore, soon after Dr Furchgott's discovery, it 
became clear that endothelial cells not only release 
relaxing factors but also produce contracting 
substances including endothelin. The release of 
endothelium-derived vasoactive subtances is 
controlled by a host of neuromediators and by shear 
forces exerted by the blood flowing in the blood 
vessel. Under physiological conditions, a precise and 
balanced release of relaxing and contracting factors 
contributes to appropriate organ perfusion. However, 
this balance is altered in diseases such 
atherosclerosis, diabetes, chronic heart failure, 
coronary artery disease or hypertension [1]. 
A decrease in nitric oxide (NO) bioavailability 
has been proposed to contribute to endothelial 
dysfunction and increased peripheral resistances 
during essential arterial hypertension. Given that 
arginine is a substrate for both arginase and NO 
synthase, arginase activity may be a critical factor in 
NO bioavailability [2]. 
Because of high activity of arginase – the 
enzyme destroying L-arginine in a mucous 
membrane of thin intestine, 40% of arginine arriving 
with food destroyed in the course of absorption, and 
its remaining quantity arrives into a portal vein. 
Accepting the comprehensibility of L-arginine 
connected with protein for 90%, it is possible to 
consider, that only 50% of alimentary arginine goes 
to system circulation. The arginase is an enzyme of 
urea cycle, that hydrolyze L-arginine to ornithine and 
urea. There are two isoforms of  this enzyme. 
Arginase I is constitutive, and "extrahepatic" arginase 
(arginase II) is induced in vessel endothelium cells by 
lipopolysaccharids and interferon. [3]. 
Using the concept of preferred structures and 
methods of computer modeling techniques developed 
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synthesis of phenolic compounds containing a 
heteroatom directly related and heterocyclic 
structural fragments. The design of the molecular 
structures of these low molecular weight compounds 
performed using modern medical and chemical 
approaches, and involves a high endotelio- and 
cardioprotective activity of compounds obtained. 
During in vitro enzymatic studies essey was designed 
to find inhibitors of arginase I and arginase II. 
Extensive 100K sckrining to find inhibitors of 
arginase II was conducted. For one of the most active 
hits performed studies allowed the development of a 
formulation, study its pharmacological activity and 
toxicological safety. 
The purpose of research – the study of 
cardioprotective activity endotelio- and finished 
dosage forms – tablets, film-coated, containing 10 mg 
of phenolic nature KUD-975. 
MATERIAL AND METHODS OF 
RESEARCH 
The experiments were performed on white rats 
of males of the Wistar line weighting 180-200 g (N = 
10 animals in the group). To model endothelial 
dysfunction, N-nitro-L-arginine methyl ester (L-
NAME) was administered intraperitoneally at a dose 
of 25 mg / kg / day. The finished dosage form-film-
coated tablets containing 10 mg of KUD975 were 
administered intragastrically, 30 minutes prior to 
administration of L-NAME, in a dose 3 mg / kg once 
a day for 7 days. Intact animals were injected 
intragastrically with a 1% starch solution at a dose of 
10 ml / kg for 7 days. 
On the 8th day from the beginning of the 
experiment, under anesthesia (chloral hydrate 300 mg 
/ kg), a catheter was inserted into the left carotid 
artery to record blood pressure values (BP), bolus 
administration of pharmacological agents was 
performed in the femoral vein. The parameters of 
hemodynamics: systolic blood pressure (SBP), 
diastolic blood pressure (DBP) and heart rate  are 
measured continuously through the "Biopac" 
hardware-software complex and the computer 
program "Acqknowledge 3.8.1". In addition to blood 
pressure measurement, a number of functional tests 
were performed, followed by an assessment of 
changes in hemodynamic parameters (SBP, DBP, 
heart rate) in response to intravenous administration 
of a solution of acetylcholine (AH) at a dose of 40 μg 
/ kg at a rate of 0.1 ml per 100 g of body weight of 
the animal, as well as changes in hemodynamic 
parameters in response to intravenous administration 
of sodium nitroprusside (NP) solution at a dose of 30 
mcg / kg at the rate of 0.1 ml per 100 g of animal 
body weight [4, 5, 6, 7]. 
The degree of endothelial dysfunction in 
experimental animals, as well as the degree of its 
correction by the studied drugs, was assessed by the 
calculated coefficient of endothelial dysfunction 
(CED). This coefficient was calculated using the 
formula: CED = S BP NP / S BP AH, where S BP 
NP is the area of the triangle above the curve of 
recovery of the blood pressure, and the points of the 
smaller leg are the point of maximum fall of the 
blood pressure and the point of exit of the blood 
pressure level to the plateau when the functional test 
is performed with sodium nitroprusside, S BP AH – 
the area of the triangle above the curve of recovery of 
blood pressure when carrying out a sample with 
acetylcholine, and for the smaller of the legs take the 
difference between the end point of the bradycardic 
cardiac component and the recovery point of AD. 
Biochemical markers of endothelial dysfunction 
were the indices of concentration of stable metabolites 
of nitric oxide (Total NOx) and expression of 
endothelial NO synthase (eNOS). A modification of the 
method for the determination of stable metabolites of 
NO was used, which allows one-step quantitative 
determination of total nitrates and nitrites after 
deproteinization of blood serum. The principle of the 
method is the simultaneous reduction of nitrates to 
nitrites in the presence of chloride bath tubing and the 
reaction of diazotization followed by the development 
of color. The level of expression of endothelial nitric 
oxide synthase (e-NOS) was determined in a cell lysate 
by the method of Hendrickson (Metelskaya VA, 
Gumanova NG, 2002). Detection of the eNOS band 
was performed by the enhanced chemiluminescence 
(ECL) method [4, 6]. 
A study of myocardial contractility after 
pathology modeling was carried out in anesthetized 
rats, which were on controlled respiration. The cavity 
of the left ventricle was probed with a needle through 
the apex of the heart and the parameters of 
cardihaemodynamics (left ventricular pressure, 
maximum speed of reduction (+ dp / dt max), 
maximum speed were recorded by means of the 
hardware complex "Biopac" (USA) and computer 
program "Acqknowledge 3.8.1" Relaxing (-dp / dt 
max), heart rate (heart rate). 
To assess the functional capabilities of the 
myocardium in animals, loading tests were performed 
in the sequence shown: 
1. Test for adrenoreactivity – intravenous one-
stage administration of a solution of adrenaline 
hydrochloride 1 * 10-5 mol / l, calculated on the basis 
of 0.1 ml per 100 g of body weight. When this 
sample was performed, an assessment was made of 
the maximum elevation of left ventricular pressure 
(LVP) in response to the administration of 
epinephrine. 
2. Resistance load – clamping of the ascending 
aorta by 30 sec. After this test, the expiration of the 
 Pharmacological efficacy of an inhibitor of arginase-2 KUD975 with L-NAME-induced endothelial 
dysfunction / K.V. Kudryavtsev, M.V. Korokin, O.S. Gudyrev // Research result: pharmacology and 
clinical pharmacology. – 2017. – Vol. 3, №1. – P. 10-17. 
12 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
myocardial reserve (expressed as a percentage) was 
calculated, which is equal to the ratio of the LVP 
increment at the 5th second of the aortic clamping to 
the increase in the LVP at the 25th second of the 
aortic clamping 
3. 3-minute hypoxia followed by reoxygenation. 
After the test, the maximum LDL was evaluated in 
response to the resumption of pulmonary ventilation. 
Histological examination of the heart is carried out 
for morphological confirmation of the development of 
simulated pathological processes and in the complex 
evaluation of the effectiveness of substances. The 
material is fixed in 10% formalin, followed by pouring 
into paraffin. The stains of hematoxylin and regimen are 
used to detect early damage to cardiomyocytes, 
according to Van Gison. With the morphometry of the 
heart, a method for determining the diameter of 
cardiomyocytes will be used. 
Reliability of changes in absolute parameters 
was determined by the difference method of 
variational statistics with finding the mean values of 
the shifts (M), the mean of the arithmetic mean (±m), 
and the probability of possible error (p) from the 
Student's tables. Differences were assessed as 
significant at p <0.05. Statistical calculations were 
carried out using Microsoft Excel 7.0. 
RESULTS  
According to the study design, endothelial 
dysfunction was simulated daily for 7 days by 
intraperitoneal injection of L-NAME (25 m / kg). 
Animals in the groups were randomized by sex and 
weight. 
The investigated KUD975 tablets were 
administered intragastrically with a probe, once a day 
30 minutes before L-NAME for 7 days. 
According to the protocol on the eighth day, an 
anesthetized animal was taken into an experiment. 
The effect of test compounds on baseline blood 
pressure in anesthetized rats with modeling of  
L-NAME-induced pathology is presented in Figure 6.1. 
Daily, for 7 days, intraperitoneal injection  
of L-NAME resulted in a statistically significant 
increase in blood pressure (Fig. 1)  
 
 
 
Figure 1. Effect of KUD975 on blood pressure in modeling endothelial dysfunction (mmHg, N = 10 animals in the group) 
1- Intact animals; 2 –L-NAME; 3 – L-NAME + KUD975 
Notes: here and below: 
1* – p <0.05 – in comparison with the group of intact animals;  
2** – p <0.05 – in comparison with the group of animals that received L-NAME 
 
It was found that the KUD-975 GLF statistically 
significantly reduces the initial arterial pressure in the 
background of modeling of L-NAME induced 
endothelial dysfunction. 
In the figure 2. The results of functional tests on the 
endothelium-dependent (acetylcholine 40 μg / kg IV) 
and endothelium-independent (nitroprusside  
30 mg / kg IV) vascular relaxation in animals with L-
NAME induced pathology in the background of 
treatment with the drugs studied. 
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Figure 2. The values of the coefficient of endothelial dysfunction in the simulation of L-NAME induced deficiency  
of nitric oxide and its correction with the help of the developed KUD975 (standard units, N = 10 animals in the group)  
1 – Intact animals; 2 –L-NAME; 3 – L-NAME + KUD975 
 
 
The processing of the obtained experimental 
data made it possible to establish that the developed 
finished dosage form at a dose of 3 mg / kg had an 
endothelioprotective effect, which resulted in a 
statistically significant decrease in the endothelial 
dysfunction coefficient and an absolute achievement 
by the coefficient of endothelial dysfunction in the 
group of animals receiving KUD975 of the CED 
level of intact animals. 
When analyzing the absolute values of areas 
over the blood pressure restoration curves, it was 
found that the optimal ratio of endothelium 
dependent and endothelium independent 
vasodilatation (close to the animals in the control 
series) was characteristic of the group of animals 
receiving KUD-975 tablets. This fact indicates the 
pronounced effect of KUD-975 on endotheliocytes 
and the nitric oxide synthesis system. 
The results of studying the effect of test 
compounds on the expression of endothelial NO 
synthase are presented in Figure 3. 
 
 
Figure 3. Influence of the developed KLGF KUD975 on eNOS expression (% Of control, N = 10 animals per group). 
1- Intact animals; 2 – L-NAME; 3 – L-NAME + KUD975. 
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It was found that the use of the developed tablets  
KUD975 did not lead to a significant increase in 
eNOS expression. 
The NO-producing function of the endothelium 
was studied on the basis of the concentration of stable 
NOx metabolites (Figure 4). 
 Modeling of L-NAME induced endothelial 
dysfunction led to a decrease in the concentration of 
stable metabolites of the oxide by more than 2 times. 
A statistically significant increase in the 
concentration of stable metabolites of nitric oxide 
was observed in the group of animals receiving 
KUD975 (Figure 4). A marked increase in the 
concentration of the final stable metabolites of nitric 
oxide was found in the group of animals that received 
KUD975, which, along with the normalization of 
vasodilatation, indicates a pronounced 
endothelioprotective effect of the finished drug 
formulation studied.  
 
Figure 4. Effect of test compounds on the concentration of stable metabolites  
of nitric oxide (NOx) (μmol / L, N = 10 animals in the group). 
1 – Intact animals; 2 – L-NAME; 3 – L-NAME + KUD975. 
 
 
When transferring animals to controlled 
respiration and catheterization of the left ventricular 
cavity of the heart, it was found that L-NAME-
induced deficiency of nitric oxide was characterized 
by hyperdynamic shifts in the initial 
cardiohemodynamics (Table 1). The test for 
adrenoreactivity, resistance loading and posthypoxic 
reactivity of the myocardium were accompanied by 
significantly higher values of LVP and velocity 
indices (Tables 1, 2, 3). 
The effect of the finished dosage form on initial 
parameters of cardihaemodynamics is presented in 
Table 1. The hypodynamic action of the test 
compounds was revealed in the use of tablets 
KUD975, which resulted in a decrease in absolute 
LVP values, + dp / dt, -dp / dt (Table 1). 
Load evaluation was performed to evaluate the 
functional capabilities of the myocardium in animals 
with L-NAME induced endothelial dysfunction. 
The adrenoreactivity test was characterized by a 
pronounced increase in the absolute values of the 
LVP, + dp / dt, -dp / dt. 
Table 1  
Changes in the ratios of left ventricular contractility  
of the rat heart in the modeling of L-NAME induced 
endothelial dysfunction and its correction with the help 
of KUD975 (M ± m) 
Group 
of 
animals 
LVP 
mm Hg. 
+dp/dtmax 
mm Hg /s 
-dp/dtmax 
mm Hg /s 
Heart 
rate 
Intact 
animals  
112,2±8,6 6707,4±154,1 4594±151,6 350,8±11,7 
L-
NAME 
189,8±8,0* 8274,8±250,6* 5266±87,2* 358,4±8,7 
L-
NAME 
+ KUD-
975  
126,9±3,0** 7238,4±105,2** 5171,5±50,3* 351,4±9,2 
 
Notes 
1 * – p <0,05 – in comparison with the group of intact 
animals 
2 ** – p <0.05 – in comparison with the group of animals 
that received L-NAME 
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The analysis of the obtained experimental data 
made it possible to establish a statistically significant 
decrease in the maximum LVP during the 
adrenoreactivity test in a series of experiments with 
the KUD975. (Figure 5). 
 
Figure 5. Effect of KUD975 on the maximum arterial pressure in the cavity of the left ventricle  
of the heart when carrying out a sample for adrenoreactivity. (Mm Hg, N = 10 animals per group). 
1 – Intact animals; 2 – L-NAME; 3 – L-NAME + KUD975 
 
When carrying out the sample for the resistance  
load, the  results  are  comparable  with  those of the 
adrenoreactivity test (Figure 5).  
 
Figure 6. Effect of the KUD975 GLF on the depletion of the myocardial reserve when carrying out the sample  
on the resistance load (%, N = 10 animals in the group) 
1 – Intact animals; 2 – L-NAME; 3 – L-NAME + KUD975 
 
The results of the hypoxic test are presented in 
Table 2. Modeling of L-NAME induced endothelial 
dysfunction led to an increase in the numbers of 
maximum LVP with simultaneous, statistically 
significant reduction in heart rate and rate of 
myocardial contractility at the peak of 
reoxygenation. 
As can be seen from the presented data, in the 
group of animals that received the tablets KUD975 
values of the maximum rate of contraction and 
relaxation, the IPS at the peak of reoxygenation 
exceeded those in the L-NAME-induced pathology 
group, and the LVP value in these groups was 
significantly lower than in animals with Modeled 
pathology. A lower LVP value with an increase in 
the rate and heart rate indicates an effective 
adjustment of the vascular tone regulation under the 
action of the phenolic compounds studied (Table 2).
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Table 2  
Changes in the ratios of left ventricular contractility in rat hearts in a sample with acute hypoxia and reoxygenation in 
the modeling of L-NAME-induced endothelial dysfunction and its correction with the help of  KUD975 tablets (M ± m) 
Group of animals 
LVP 
mm Hg. 
+dp/dtmax 
mm Hg /s 
-dp/dtmax 
mm Hg /s 
Heart rate 
Intact animals  191,7±5,5 8076,6±562 5044,8±499,2 242,2±8,5 
L-NAME 229,6±4,2* 7001,8±729,4 4184,3±234,7 198,9±5,4* 
L-NAME + KUD-975  194,1±4,4** 8205,5±571,6 4622,5±439,8 256,9±9,7** 
Notes: 
1 * – p <0,05 – in comparison with the group of intact animals 
2 ** – p <0.05 – in comparison with the group of animals that received L-NAME 
 
 
Morphological examination of the heart showed 
no signs of myocardial damage in the group of 
animals treated with KUD975. Myocardium had a 
homogeneous structure with a uniform density of 
cardiomyocyte location and stroma. Cardiomyocytes 
with a fine-fibrillar cytoplasmic structure, 
distinguishable by transverse striation, centrally 
located monomorphic nuclei with moderately 
condensed chromatin. Stroma streaks are fine-
fibrous, with uniform saturation with fibroblastic 
elements. There were no differences in different 
zones of the myocardium (subendocardial, 
subepicardial, middle regions). (Figure 7). 
 
Figure 7. Histological structure of the myocardium in animals receiving KUD975 at a dose of 3 mg / kg on day 8 of the 
experiment: a homogeneous structure of the myocardium with a uniform blood filling of capillaries between cardiomyocytes, 
moderately pronounced dilatation and plethora of venules in the subepicardial zone (B). X200 
 
B 
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The process of NO synthesis involves firstly the 
oxidation of arginine to NG-hydroxy-l-arginine (NHA) 
using nicotinamide adenine dinucleotide phosphate 
(NADPH) and O2 catalyzed by NOS [8]. The second 
step involves the production of NO when NHA is 
converted to l-citrulline via NOS. The actions of NOS 
are accelerated by the cofactors flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN), and 
tetrahydrobiopterin (BH4). In the absence of its 
substrate l-arginine or its cofactor BH4, eNOS 
uncouples and produces ROS, making it one of the four 
major enzymes involved in the production of vascular 
ROS. (The others are xanthine oxidase, 
NADH/NADPH, the mitochondrial electron transport 
chain, and eNOS). NOS uncoupling is an important 
contributor to endothelial dysfunction and plays a 
crucial role in the cardiovascular phenotype. Arginase, a 
critical urea cycle enzyme, also utilizes l-arginine. It 
thereby directly competes with eNOS for their common 
substrate l-arginine and constrains its availability to 
eNOS, compromising NO production and increasing 
the production of ROS by NOS uncoupling [9, 10, 11]. 
Arginase, which is present in two isoforms (arginase I 
in the liver and arginase II extrahepatic) catalyzes the 
final step of the urea cycle yielding l-ornithine and urea 
from l-arginine. Arginase II appears to be the 
predominant isoform in human endothelial cells [12] 
and is highly compartmentalized. There appear to be at 
least three distinct pools of l-arginine that are spatially 
confined and regulated by different transporters and 
enzymes [13]. 
In this regard, an actual problem is to find novel 
compounds, selective inhibitors of arginase II study 
and correction capabilities farmakological correction 
endothelial dysfunction with these compounds. 
This study shows that the developed tablets, 
film-coated, containing 10 mg of phenolic nature 
KUD-975, have a pronounced endothelioprotective 
effect. Thus, we can talk about endothelio- and 
cardioprotective effects of this group of substances 
and their term used to treat cardiovascular disease. 
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